AbCellera founder and CEO Carl Hansen (L) and Rallybio CEO Martin Mackay

Rally­bio, Ab­Cellera form new part­ner­ship around an­ti­bod­ies for rare dis­ease

Two biotechs that have been work­ing heav­i­ly on dif­fer­ent stages of an­ti­body can­di­date de­vel­op­ment over the past sev­er­al years are look­ing to work to­geth­er to find po­ten­tial can­di­dates for rare dis­eases.

Cana­di­an-based Ab­Cellera and Con­necti­cut-based Rally­bio have en­tered a strate­gic part­ner­ship to find, de­vel­op and com­mer­cial­ize an­ti­bod­ies pri­mar­i­ly for rare dis­eases. The mul­ti-year, mul­ti-tar­get deal will seek to com­bine Ab­Cellera’s an­ti­body “dis­cov­ery en­gine” with Rally­bio’s ex­per­tise in rare dis­eases. How­ev­er, the dol­lar amount for the deal was not dis­closed.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters